Bone Biologics Corp Warrants
BBLGW
1 hedge funds and large institutions have $805 invested in Bone Biologics Corp Warrants in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 4 closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
80% less funds holding
Funds holding: 5 → 1 (-4)
90% less capital invested
Capital invested by funds: $8.27K → $805 (-$7.47K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.3K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$1.97K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.03K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$10 |
| 5 |
CS
Clear Street
New York
|
-$3 |
BBLGW Hedge Fund Activity: Q2 2023 in Review
1 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q2 2023, worth a combined $805 — down 90% from $8.27K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of BBLGW and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, exiting entirely with an estimated $4.3K sold.
- 1 institutional investor held Bone Biologics Corp Warrants (BBLGW) as of Q2 2023, down from 5 in Q1 2023.
- Funds reported $805 of Bone Biologics Corp Warrants stock for Q2 2023, down 90% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q2 2023 and 4 closed out, a net change of -4 holders.
- The largest Bone Biologics Corp Warrants seller in Q2 2023 was Sabby Management, an estimated $4.3K sold.
Based on aggregated 13F filings for Q2 2023.